Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Recruiting

Phase 1

Phase 2

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Sponsor:

AstraZeneca

Code:

NCT05797168

Conditions

Ovarian Cancer

Lung Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

AZD5335

Saruparib (AZD5305)

Bevacizumab

Carboplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-22. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-04-08.